Abnormal collagen V deposition in dermis correlates with skin thickening and disease activity in systemic sclerosis

Carregando...
Imagem de Miniatura
Citações na Scopus
47
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Citação
AUTOIMMUNITY REVIEWS, v.11, n.11, Special Issue, p.827-835, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: The physiological and mechanical properties of the skin, the primary tissue affected by systemic sclerosis, depend on the assembly of collagen types I, Ill and V, which form heterotypic fibers. Collagen V (COLV) regulates heterotypic fiber diameter, and the maintenance of its properties is important for maintaining normal tissue architecture and function. Based on a COLV-induced experimental SSc model, in which overexpression of abnormal COLV was a prominent feature, we assumed that this abnormality could be present in SSc patients and could be correlated to disease duration, skin thickening and disease activity. Methods: Skin biopsies from 18 patients (6 early-stage and 12 late-stage) and 10 healthy controls were studied. Skin thickening assessment was performed with the Modified Rodnan Skin Score (MRSS), and activity was calculated using the Valentini Disease Activity Index. Morphology, morphometry of COLV deposition in dermis, as well as, quantitative RT-PCR and 3D-reconstruction of the dermal fibroblast culture were performed. Results: Structurally abnormal COLV was overexpressed in SSc skin, mainly in the early stages of the disease, when compared to normal controls and late-stage. A positive correlation between COLV expression and MRSS and disease activity was observed. Collagen V alpha-1 and alpha-2 mRNA expression levels were higher in SSc. Tridimensional reconstruction of SSc dermal heterotypic fibers confirmed the presence of atypical COLV. Conclusion: Increased synthesis of abnormal COLV and its correlation with disease stage, activity and MRSS suggest that this collagen can be a possible trigger involved in the pathogenesis of SSc.
Palavras-chave
Systemic sclerosis, Type V collagen, Skin, Modified Rodnan Skin Score, Valentini Disease Activity Index
Referências
  1. Behr J, 2008, RHEUMATOLOGY, V47, pV65, DOI 10.1093/rheumatology/ken313
  2. Bezerra MC, 2006, ARCH DERMATOL RES, V298, P51, DOI 10.1007/s00403-006-0645-5
  3. Bharat A, 2006, AM J TRANSPLANT, V6, P1799, DOI 10.1111/j.1600-6143.2006.01383.x
  4. BIRK DE, 1990, J CELL SCI, V95, P649
  5. Birk DE, 2001, MICRON, V32, P223, DOI 10.1016/S0968-4328(00)00043-3
  6. Brinckmann J, 2005, MATRIX BIOL, V24, P459, DOI 10.1016/j.matbio.2005.07.002
  7. Callado MRM, 2007, IMMUNOLOGY, V122, P38, DOI 10.1111/j.1365-2567.2007.02610.x
  8. Chanut-Delalande H, 2004, MOL CELL BIOL, V24, P6049, DOI 10.1128/MCB.24.13.6049-6057.2004
  9. CLEMENTS P, 1995, J RHEUMATOL, V22, P1281
  10. Coelho JC, 2000, GENET MOL BIOL, V23, P269
  11. Corriveau MP, 2009, J PATHOL, V217, P534, DOI 10.1002/path.2482
  12. Cotton SA, 1999, J PATHOL, V189, P273, DOI 10.1002/(SICI)1096-9896(199910)189:2<273::AID-PATH413>3.3.CO;2-W
  13. de Oliveira CC, 2009, CLINICS, V64, P577, DOI 10.1590/S1807-59322009000600014
  14. Derk CT, 2003, AUTOIMMUN REV, V2, P181, DOI 10.1016/S1568-9972(03)00005-3
  15. FLEISCHMAJER R, 1978, ARTHRITIS RHEUM, V21, P418, DOI 10.1002/art.1780210404
  16. Gao MQ, 2010, J CELL SCI, V123, P3507, DOI 10.1242/jcs.072900
  17. Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002
  18. Haque MA, 2002, J IMMUNOL, V169, P1542
  19. Henkel W, 2007, J PROTEOME RES, V6, P4269, DOI 10.1021/pr070318r
  20. Jaramillo A, 1999, TRANSPLANTATION, V67, P1155, DOI 10.1097/00007890-199904270-00012
  21. Laplante P, 2010, CELL DEATH DIFFER, V17, P291, DOI 10.1038/cdd.2009.124
  22. Liu T, 2008, J HUAZHONG U SCI-MED, V28, P599, DOI 10.1007/s11596-008-0525-7
  23. Luparello C, 2005, J CELL PHYSIOL, V202, P411, DOI 10.1002/jcp.20131
  24. Malfait F, 2010, GENET MED, V12, P597, DOI 10.1097/GIM.0b013e3181eed412
  25. Marangoni RG, 2011, ARTHRITIS RHEUM S, V62, pS253
  26. Marangoni RG, 2010, CLIN EXP RHEUMATOL S, V5, P31
  27. Pannu J, 2006, ARTHRITIS RHEUM, V54, P3011, DOI 10.1002/art.22063
  28. Parra ER, 2010, EUR J CLIN INVEST, V40, P110, DOI 10.1111/j.1365-2362.2009.02224.x
  29. Parra ER, 2009, CLIN RESPIR J, V3, P135, DOI 10.1111/j.1752-699X.2008.00118.x
  30. QUINONES F, 1986, AM REV RESPIR DIS, V134, P1163
  31. RIENTE L, 1995, CLIN EXP IMMUNOL, V102, P354
  32. Roulet M, 2007, CELL TISSUE RES, V327, P323, DOI 10.1007/s00441-006-0294-1
  33. Sakkas LI, 2002, J IMMUNOL, V168, P3649
  34. Sakkas LI, 2004, ARTHRITIS RHEUM, V50, P1721, DOI 10.1002/art.20315
  35. Sargent JL, 2010, J INVEST DERMATOL, V130, P694, DOI 10.1038/jid.2009.318
  36. Schmittgen TD, 2001, METHODS, V25, P402
  37. Sorrel MJ, 2004, J CELL PATHOL, V200, P134
  38. Souza P, 2010, HUM PATHOL, V41, P239, DOI 10.1016/j.humpath.2009.07.018
  39. Spiess K, 2007, CONNECT TISSUE RES, V48, P99, DOI 10.1080/03008200601166194
  40. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria, 1980, ARTHRITIS RHEUM, V23, P581
  41. Teodoro WR, 2004, PATHOL RES PRACT, V200, P681, DOI 10.1016/j.prp.2004.05.007
  42. Valentini G, 2003, CLIN EXP RHEUMATOL, V21, pS39
  43. Velosa APP, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-1
  44. Velosa APP, 2007, ARCH DERMATOL RES, V299, P177, DOI 10.1007/s00403-007-0735-z
  45. Wells AU, 2008, RHEUMATOLOGY, V47, pV59, DOI 10.1093/rheumatology/ken271
  46. WHITE B, 1995, ARTHRITIS RHEUM, V38, P351, DOI 10.1002/art.1780380309
  47. Wigley FM, 2003, RHEUMATOLOGY, P1463
  48. Yasufuku K, 2002, TRANSPLANTATION, V73, P500, DOI 10.1097/00007890-200202270-00002
  49. Yasufuku K, 2001, AM J RESP CELL MOL, V25, P26